June 19, 2024

Medical Trend

Medical News and Medical Resources

Oxford COVID-19 vaccine: Trials Continue While Adverse Reactions in India

Oxford COVID-19 vaccine: Trials Continue While Adverse Reactions in India

Oxford COVID-19 vaccine: Trials Continue While Adverse Reactions in India. An Indian man developed serious adverse symptoms after being vaccinated with the COVID-19 pneumonia vaccine developed by Oxford University and the British pharmaceutical company AstraZeneca. However, senior Indian officials said yesterday that the vaccine experiment will not be interrupted and the schedule of vaccine delivery will not be affected.

Oxford COVID-19 vaccine: Trials Continue While Adverse Reactions in India

The Hindustan Times reported today that Rajesh Bhushan, Deputy Minister of Health and Family Welfare and Balram Bhargava, Director-General of the Indian Council of Medical Research (ICMR) attended an official briefing yesterday. Make the above statement.

Covishield, a vaccine developed by Oxford University and AstraZeneca for the Coronavirus Disease 2019 (COVID-19, commonly known as Wuhan pneumonia), had died after vaccination in Brazil.

Recently, a man in India suffered from severe neurological symptoms after participating in experimental vaccination. He filed a lawsuit with the Serum Institute for a compensation of 50 million rupees (about 19.35 million New Taiwan dollars), which aroused the attention of the outside world.

The Serum Institute issued a statement reiterating the safety of the vaccine and pointed out that the symptoms of volunteer subjects were immune responses.

The official representative of Bushan stated that after assessing the situation of volunteers after being vaccinated, the government decided that there is no need to stop the experiment of this vaccine in India; this incident will not affect the schedule of vaccine-related procedures in any way.

Bushan said that the government has five safeguards for vaccine clinical trials, including two independent expert groups to monitor vaccine clinical trials, understand the process, and review experimental data. Indian regulatory agencies will also take care of vaccine trials. Case review.

The Serum Institute of India, the world’s largest vaccine manufacturer, said on November 28 that it would apply for an emergency use permit for the Covishield vaccine within two weeks. Indian Prime Minister Modi visited the Serum Institute of India the next day to understand the status of vaccine production. He has instructed the central government and relevant provinces to research and prepare vaccine distribution and storage.

The Serum Institute expects that the Covishield vaccine will obtain an official emergency use license in the next few months or even at the end of the year, and will administer the vaccine to the 2.5 million to 3 million medical staff and basic service personnel receiving the vaccination in the first phase of the Indian government plan .

Modi also hopes that under the government’s requisition, India can obtain 300 to 400 million doses of vaccine for the Indian people to administer by July next year.

Therefore, although some Indian men developed adverse symptoms after being vaccinated with Covishield, the Indian government still decided to continue to vaccinate those in need according to the original plan.

In addition, Bushan clarified that the Indian government has never talked about vaccinating people across the country.

Bagava said that if “key populations” have been vaccinated and the chain of virus transmission is broken, it may not be necessary to vaccinate everyone. However, Bagava did not explain how to break the chain of virus transmission.

In India, the number of new cases of Wuhan pneumonia in a single day has dropped from 80,000 to 90,000 at the peak to more than 40,000. The cumulative number of cases continued to rise. As of this morning, the cumulative number of cases was nearly 9.5 million, and the death toll reached 138,159. The cumulative number of cases still ranks the second worst-hit area in the world.